# Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis

> **NCT03407001** · EARLY_PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Cirrhosis

## Interventions

- **PROCEDURE:** Contrast-Enhanced Ultrasound
- **DRUG:** Sulfur Hexafluoride Lipid Microspheres
- **PROCEDURE:** Ultrasound

## Key facts

- **NCT ID:** NCT03407001
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-12
- **Primary completion:** 2020-09-15
- **Final completion:** 2020-09-15
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03407001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03407001, "Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03407001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*